Literature DB >> 31984450

High-density lipoprotein-mediated cardioprotection in heart failure.

Ampadu O Jackson1,2, Jun Meng3, Huifang Tang4, Kai Yin5,6.   

Abstract

The prevalence of heart failure (HF), including reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF), has increased significantly worldwide. However, the prognosis and treatment of HF are still not good. Recent studies have demonstrated that high-density lipoprotein (HDL) plays an important role in cardiac repair during HF. The exact role and mechanism of HDL in the regulation of HF remain unexplained. Here, we discuss recent findings regarding HDL in the progression of HF, such as the regulation of excitation-contraction coupling, energy homeostasis, inflammation, neurohormone activation, and microvascular dysfunction. The effects of HDL on the regulation of cardiac-related cells, such as endothelial cells (ECs), cardiomyocytes (CMs), and on cardiac resident immune cell dysfunction in HF are also explained. An in-depth understanding of HDL function in the heart may provide new strategies for the prevention and treatment of HF.

Entities:  

Keywords:  Heart failure; High-density lipoprotein; Inflammation; Neurohormones; Nitrosative stress

Mesh:

Substances:

Year:  2021        PMID: 31984450     DOI: 10.1007/s10741-020-09916-0

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  117 in total

1.  Endothelial function is disturbed in a hypertensive diabetic animal model of HFpEF: Moderate continuous vs. high intensity interval training.

Authors:  Zelia Schmederer; Natale Rolim; T Scott Bowen; Axel Linke; Ulrik Wisloff; Volker Adams
Journal:  Int J Cardiol       Date:  2018-08-30       Impact factor: 4.164

Review 2.  Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure.

Authors:  Vaibhav B Patel; Jiu-Chang Zhong; Maria B Grant; Gavin Y Oudit
Journal:  Circ Res       Date:  2016-04-15       Impact factor: 17.367

3.  Pulmonary Congestion by Lung Ultrasound in Ambulatory Patients With Heart Failure With Reduced or Preserved Ejection Fraction and Hypertension.

Authors:  Kristin H Dwyer; Allison A Merz; Eldrin F Lewis; Brian L Claggett; Daniela R Crousillat; Emily S Lau; Montane B Silverman; Julie Peck; Jose Rivero; Susan Cheng; Elke Platz
Journal:  J Card Fail       Date:  2018-03-01       Impact factor: 5.712

4.  High-Density Lipoprotein Particle Subfractions in Heart Failure With Preserved or Reduced Ejection Fraction.

Authors:  Wynn G Hunter; Robert W McGarrah; Jacob P Kelly; Michel G Khouri; Damian M Craig; Carol Haynes; G Michael Felker; Adrian F Hernandez; Eric J Velazquez; William E Kraus; Svati H Shah
Journal:  J Am Coll Cardiol       Date:  2019-01-22       Impact factor: 24.094

5.  Antibodies to receptors are associated with biomarkers of inflammation and myocardial damage in heart failure.

Authors:  Anders Lund; Lasse Melvaer Giil; Grete Slettom; Ottar Nygaard; Harald Heidecke; Jan Erik Nordrehaug
Journal:  Int J Cardiol       Date:  2017-10-05       Impact factor: 4.164

6.  Creation of a restrictive atrial communication in heart failure with preserved and mid-range ejection fraction: effective palliation of left atrial hypertension and pulmonary congestion.

Authors:  Anna Bauer; Markus Khalil; Monika Lüdemann; Jürgen Bauer; Anoosh Esmaeili; Roberta De-Rosa; Norbert F Voelkel; Hakan Akintuerk; Dietmar Schranz
Journal:  Clin Res Cardiol       Date:  2018-04-16       Impact factor: 5.460

7.  N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status.

Authors:  Søren L Kristensen; Ulrik M Mogensen; Pardeep S Jhund; Rasmus Rørth; Inder S Anand; Peter E Carson; Akshay S Desai; Bertram Pitt; Marc A Pfeffer; Scott D Solomon; Michael R Zile; Lars Køber; John J V McMurray
Journal:  Circ Heart Fail       Date:  2019-03       Impact factor: 8.790

8.  Long-Term Survival and Apolipoprotein A1 Level in Chronic Heart Failure: Interaction With Tumor Necrosis Factor α -308 G/A Polymorphism.

Authors:  Tímea Gombos; Zsolt Förhécz; Zoltán Pozsonyi; Lívia Jánoskuti; Zoltán Prohászka; István Karádi
Journal:  J Card Fail       Date:  2016-06-16       Impact factor: 5.712

9.  A mouse model for the most common form of heart failure.

Authors:  Dulguun Amgalan; Richard N Kitsis
Journal:  Nature       Date:  2019-04       Impact factor: 49.962

10.  Nitrosative stress drives heart failure with preserved ejection fraction.

Authors:  Gabriele G Schiattarella; Francisco Altamirano; Dan Tong; Kristin M French; Elisa Villalobos; Soo Young Kim; Xiang Luo; Nan Jiang; Herman I May; Zhao V Wang; Theodore M Hill; Pradeep P A Mammen; Jian Huang; Dong I Lee; Virginia S Hahn; Kavita Sharma; David A Kass; Sergio Lavandero; Thomas G Gillette; Joseph A Hill
Journal:  Nature       Date:  2019-04-10       Impact factor: 49.962

View more
  1 in total

1.  The Influence of Hypertensive Therapies on Circulating Factors: Clinical Implications for SCFAs, FGF21, TNFSF14 and TNF-α.

Authors:  Aaron L Magno; Lakshini Y Herat; Márcio G Kiuchi; Markus P Schlaich; Natalie C Ward; Vance B Matthews
Journal:  J Clin Med       Date:  2020-08-26       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.